WO2005039638A3 - Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor - Google Patents

Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor Download PDF

Info

Publication number
WO2005039638A3
WO2005039638A3 PCT/EP2004/011677 EP2004011677W WO2005039638A3 WO 2005039638 A3 WO2005039638 A3 WO 2005039638A3 EP 2004011677 W EP2004011677 W EP 2004011677W WO 2005039638 A3 WO2005039638 A3 WO 2005039638A3
Authority
WO
WIPO (PCT)
Prior art keywords
heart failure
angiotensin
therapeutic agent
receptor antagonist
matrix metalloproteinase
Prior art date
Application number
PCT/EP2004/011677
Other languages
French (fr)
Other versions
WO2005039638A2 (en
Inventor
Yasuki Kihara
Original Assignee
Boehringer Ingelheim Int
Ono Pharmaceutical Co
Yasuki Kihara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Ono Pharmaceutical Co, Yasuki Kihara filed Critical Boehringer Ingelheim Int
Publication of WO2005039638A2 publication Critical patent/WO2005039638A2/en
Publication of WO2005039638A3 publication Critical patent/WO2005039638A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

It is an object of the present invention to provide an agent effective for preventing and/or treating heart failure and/or cardiac hypertrophy. A preventive and/or therapeutic agent for heart failure and/or cardiac hypertrophy, comprising an angiotensin II receptor antagonist and a matrix metalloproteinase inhibitor.
PCT/EP2004/011677 2003-10-21 2004-10-15 Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor WO2005039638A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003361138A JP2005126338A (en) 2003-10-21 2003-10-21 Cardiac failure therapeutic agent
JP2003-361138 2003-10-21

Publications (2)

Publication Number Publication Date
WO2005039638A2 WO2005039638A2 (en) 2005-05-06
WO2005039638A3 true WO2005039638A3 (en) 2005-07-21

Family

ID=34509930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/011677 WO2005039638A2 (en) 2003-10-21 2004-10-15 Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor

Country Status (2)

Country Link
JP (1) JP2005126338A (en)
WO (1) WO2005039638A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030216A1 (en) * 1997-01-10 1998-07-16 Merck & Co., Inc. Use of angiotensin ii antagonists to treat symptomatic heart failure
EP1088550A1 (en) * 1999-10-01 2001-04-04 Pfizer Products Inc. alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders
EP1275391A1 (en) * 1995-06-07 2003-01-15 Sanofi-Synthelabo Pharmaceutical compositions containing irbesartan and a diuretic
WO2003015762A1 (en) * 2001-08-20 2003-02-27 Ono Pharmaceutical Co., Ltd. Remedial agent for cardiac failure
US20030078190A1 (en) * 2001-05-25 2003-04-24 Weinberg Marc S. Methods for tissue protection using highly effective inhibition of the renin-angiotensin system

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1275391A1 (en) * 1995-06-07 2003-01-15 Sanofi-Synthelabo Pharmaceutical compositions containing irbesartan and a diuretic
WO1998030216A1 (en) * 1997-01-10 1998-07-16 Merck & Co., Inc. Use of angiotensin ii antagonists to treat symptomatic heart failure
EP1088550A1 (en) * 1999-10-01 2001-04-04 Pfizer Products Inc. alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders
US20030078190A1 (en) * 2001-05-25 2003-04-24 Weinberg Marc S. Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
WO2003015762A1 (en) * 2001-08-20 2003-02-27 Ono Pharmaceutical Co., Ltd. Remedial agent for cardiac failure
EP1419767A1 (en) * 2001-08-20 2004-05-19 Ono Pharmaceutical Co., Ltd. Remedial agent for cardiac failure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PETERSON J T ET AL: "Matrix Metalloproteinase Inhibitor Development for the Treatment of HEart Failure", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 55, 21 March 2002 (2002-03-21), pages 29 - 44, XP002314260, ISSN: 0272-4391 *

Also Published As

Publication number Publication date
JP2005126338A (en) 2005-05-19
WO2005039638A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
WO2004105757A3 (en) Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
WO2005049084A3 (en) Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
WO2004032852A3 (en) Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2004039371A3 (en) Compositions of cyclooxygenase-2 selective inhibitors and nmda receptor antagonists for the treatment or prevention of neuropathic pain
MY138838A (en) A pharmaceutical composition comprising a combination of valsartan, amlodipine and hydrochlorothiazide
EP2362218A3 (en) Methods of monitoring the efficacy of farnesyltransferase inhibitors
EP1059100A3 (en) Combinations of CRF antagonists and renin-angiotensin system inhibitors
EP1583534A4 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
MXPA06000013A (en) Therapeutic agent for soft tissue sarcoma.
IN2005KO00312A (en)
BRPI0509420A (en) method of reducing or inhibiting angiogenesis and method of increasing efficacy of antiangiogenic agent treatment
HK1080092A1 (en) Vegf antagonists for the treatment of diabetes
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
TW200500361A (en) Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
AU2003297197A8 (en) Method for increasing the efficacy of agricultural chemicals
TW200711653A (en) Agent for inhibiting oxidation stress
EP1406648A4 (en) The use of angiotensin i derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
WO2005039638A3 (en) Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor
EP1784204A4 (en) Method of treating, preventing, inhibiting or reducing damage to cardiac tissue
ATE510543T1 (en) USE OF CILOBRADINES OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE TREATMENT OR PREVENTION OF HEART FAILURE
WO2008057313A3 (en) Methods of using e2f2 for the treatment of hypertension
AU2003239025A1 (en) Combination of an acid secretion inhibiting agent and a reflux inhibitor for the treatment of gerd
AU2003251271A1 (en) USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES
WO2004112709A3 (en) Inhibitors of cathepsin s

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP